Stock events for Emergent BioSolutions, Inc. (EBS)
Emergent BioSolutions' stock price has been volatile over the past six months. Key events include the release of Q4 and full year 2025 financial results which missed estimates and the announcement of a stock repurchase program and contract awards with the Government of Canada. The company received FDA approval for NARCAN Nasal Spray multipacks and a new carrying case. Emergent BioSolutions announced a paydown of its term loan principal and received a delivery order to supply BioThrax to the U.S. Department of War. HC Wainwright reaffirmed a buy rating, while Weiss Ratings lowered the rating to sell and Wall Street Zen downgraded the stock to hold. John D. Fowler, Jr. was appointed as a Board Director.
Demand Seasonality affecting Emergent BioSolutions, Inc.’s stock price
Specific details regarding demand seasonality are not explicitly provided. However, the company's business model suggests that demand may be influenced by government procurement cycles, national preparedness initiatives, and the emergence of health crises. The company has secured numerous modifications to MCM contracts, indicating sustained demand in the global biodefense market. NARCAN's performance has been temporarily impacted by softer demand amid government shutdown-related uncertainties, and the company faces risks from increased generic competition for NARCAN.
Overview of Emergent BioSolutions, Inc.’s business
Emergent BioSolutions, Inc. is a global life sciences company focused on preparedness and response solutions for public health threats, operating in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. The company's business is segmented into Commercial Products, Medical Countermeasure (MCM) Products, and Services (Bioservices). Key products include NARCAN Nasal Spray, BioThrax, ACAM2000, Vaxchora, Anthrasil, KLOXXADO nasal spray and Anthim. The company also provides contract development and manufacturing organization (CDMO) services.
EBS’s Geographic footprint
Emergent BioSolutions has a global presence with solutions in the United States, Canada, and internationally. Its headquarters are in Gaithersburg, Maryland, and it has facilities in various locations worldwide, including Canada, Portugal, and Singapore.
EBS Corporate Image Assessment
Specific information detailing Emergent BioSolutions' brand reputation is not explicitly available. However, the company's focus on public health threats, partnerships with government agencies, and role in national preparedness programs suggest a reputation tied to critical public health and biodefense initiatives. The company's efforts in its multiyear transformation plan indicate ongoing efforts to improve its standing.
Ownership
Emergent BioSolutions is a publicly traded company with a diverse shareholder base, including institutional, retail, and individual investors. Major institutional owners include BlackRock, Inc., The Vanguard Group Inc., and State Street Corp. The largest individual shareholder is Fuad El-Hibri, who owns 49.71% of the company.
